BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 29885409)

  • 1. Micropapillary urothelial carcinoma: evaluation of HER2 status and immunohistochemical characterization of the molecular subtype.
    Zinnall U; Weyerer V; Compérat E; Camparo P; Gaisa NT; Knuechel-Clarke R; Perren A; Lugli A; Toma M; Baretton G; Kristiansen G; Wirtz RM; Cheng L; Wullich B; Stoehr R; Hartmann A; Bertz S
    Hum Pathol; 2018 Oct; 80():55-64. PubMed ID: 29885409
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human Epidermal Growth Factor Receptor 2 Overexpression in Micropapillary and Other Variants of Urothelial Carcinoma.
    Behzatoğlu K; Yörükoğlu K; Demir H; Bal N
    Eur Urol Focus; 2018 Apr; 4(3):399-404. PubMed ID: 28753766
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The utility of p63, p40, and GATA-binding protein 3 immunohistochemistry in diagnosing micropapillary urothelial carcinoma.
    Lin X; Zhu B; Villa C; Zhong M; Kundu S; Rohan SM; Yang XJ
    Hum Pathol; 2014 Sep; 45(9):1824-9. PubMed ID: 24993315
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Micropapillary urothelial carcinoma of urinary bladder displays immunophenotypic features of luminal and p53-like subtypes and is not a variant of adenocarcinoma.
    Yang Y; Kaimakliotis HZ; Williamson SR; Koch MO; Huang K; Barboza MP; Zhang S; Wang M; Idrees MT; Grignon DJ; Eble JN; Baldridge LA; Cheng L
    Urol Oncol; 2020 May; 38(5):449-458. PubMed ID: 31740332
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of tyrosine kinase receptors HER2, EGFR, and VEGFR expression in micropapillary urothelial carcinoma with invasive urothelial carcinoma.
    Li J; Jackson CL; Yang D; Noble L; Wheeler M; MacKenzie D; Adegun T; Amin A
    Target Oncol; 2015 Sep; 10(3):355-63. PubMed ID: 25293577
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterizing the Genomic Landscape of the Micropapillary Subtype of Urothelial Carcinoma of the Bladder Harboring Activating Extracellular Mutations of ERBB2.
    Posada JM; Yakirevich E; Kamat AM; Sood A; Jacob JM; Bratslavsky G; Grivas P; Spiess PE; Li R; Necchi A; Mega AE; Golijanin DJ; Pavlick D; Huang RSP; Lin D; Danziger N; Sokol ES; Sivakumar S; Ross JS; Cheng L
    Mod Pathol; 2024 Mar; 37(3):100424. PubMed ID: 38219954
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intratumoral heterogeneity of ERBB2 amplification and HER2 expression in micropapillary urothelial carcinoma.
    Isharwal S; Huang H; Nanjangud G; Audenet F; Chen YB; Gopalan A; Fine SW; Tickoo SK; Lee BH; Iyer G; Chadalavada K; Rosenberg JE; Bajorin DF; Herr HW; Donat SM; Dalbagni G; Bochner BH; Solit DB; Reuter VE; Al-Ahmadie HA
    Hum Pathol; 2018 Jul; 77():63-69. PubMed ID: 29601842
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Distinct genetic alterations and luminal molecular subtype in nested variant of urothelial carcinoma.
    Weyerer V; Weisser R; Moskalev EA; Haller F; Stoehr R; Eckstein M; Zinnall U; Gaisa NT; Compérat E; Perren A; Keck B; Allory Y; Kristiansen G; Wullich B; Agaimy A; Hartmann A; Bertz S
    Histopathology; 2019 Dec; 75(6):865-875. PubMed ID: 31348552
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Micropapillary morphology is an indicator of poor prognosis in patients with urothelial carcinoma treated with transurethral resection and radiochemotherapy.
    Bertz S; Wach S; Taubert H; Merten R; Krause FS; Schick S; Ott OJ; Weigert E; Dworak O; Rödel C; Fietkau R; Wullich B; Keck B; Hartmann A
    Virchows Arch; 2016 Sep; 469(3):339-44. PubMed ID: 27392930
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A high frequency of activating extracellular domain ERBB2 (HER2) mutation in micropapillary urothelial carcinoma.
    Ross JS; Wang K; Gay LM; Al-Rohil RN; Nazeer T; Sheehan CE; Jennings TA; Otto GA; Donahue A; He J; Palmer G; Ali S; Nahas M; Young G; Labrecque E; Frampton G; Erlich R; Curran JA; Brennan K; Downing SR; Yelensky R; Lipson D; Hawryluk M; Miller VA; Stephens PJ
    Clin Cancer Res; 2014 Jan; 20(1):68-75. PubMed ID: 24192927
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lymphovascular invasion in micropapillary urothelial carcinoma: a study of 22 cases.
    McQuitty E; Ro JY; Truong LD; Shen SS; Zhai Q; Ayala AG
    Arch Pathol Lab Med; 2012 Jun; 136(6):635-9. PubMed ID: 22646270
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinicopathologic and Immunohistochemical Study of Combined Small Cell Carcinoma and Urothelial Carcinoma Molecular Subtype.
    Xiao GQ; Barrett MM; Yang Q; Unger PD
    Pathol Oncol Res; 2019 Jul; 25(3):889-895. PubMed ID: 29249035
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinicopathologic Analysis of Micropapillary Urothelial Carcinoma of the Upper Urinary Tract: Implications for HER2-Targeted Therapy.
    Chou LP; Hsu CW; Yang SF; Lee CT; Ou YC; Lin KC; Hu CY; Jou YC; Tsai YS; Chow NH
    Clin Genitourin Cancer; 2023 Aug; 21(4):508.e1-508.e10. PubMed ID: 37183125
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FOXA1 and CK14 as markers of luminal and basal subtypes in histologic variants of bladder cancer and their associated conventional urothelial carcinoma.
    Warrick JI; Kaag M; Raman JD; Chan W; Tran T; Kunchala S; Shuman L; DeGraff D; Chen G
    Virchows Arch; 2017 Sep; 471(3):337-345. PubMed ID: 28721490
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Invasive urothelial carcinoma exhibiting basal cell immunohistochemical markers: A variant of urothelial carcinoma associated with aggressive features.
    Mai KT; Truong LD; Ball CG; Williams P; Flood TA; Belanger EC
    Pathol Res Pract; 2015 Aug; 211(8):610-8. PubMed ID: 26100813
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunohistochemistry of cytokeratin (CK) 5/6, CD44 and CK20 as prognostic biomarkers of non-muscle-invasive papillary upper tract urothelial carcinoma.
    Jung M; Kim B; Moon KC
    Histopathology; 2019 Feb; 74(3):483-493. PubMed ID: 30286252
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Urine cytomorphology of micropapillary urothelial carcinoma.
    Zhu B; Rohan SM; Lin X
    Diagn Cytopathol; 2013 Jun; 41(6):485-91. PubMed ID: 22623512
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Morphological and molecular characteristics of HER2 amplified urothelial bladder cancer.
    Tschui J; Vassella E; Bandi N; Baumgartner U; Genitsch V; Rotzer D; Seiler R; Thalmann GN; Fleischmann A
    Virchows Arch; 2015 Jun; 466(6):703-10. PubMed ID: 25809292
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human epidermal growth factor receptor 2 expression in micropapillary urothelial carcinoma of the bladder: an analysis of 27 cases.
    Goodman AL; Osunkoya AO
    Hum Pathol; 2016 Nov; 57():160-164. PubMed ID: 27476777
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcome of patients with micropapillary urothelial carcinoma following radical cystectomy: ERBB2 (HER2) amplification identifies patients with poor outcome.
    Schneider SA; Sukov WR; Frank I; Boorjian SA; Costello BA; Tarrell RF; Thapa P; Houston Thompson R; Tollefson MK; Jeffrey Karnes R; Cheville JC
    Mod Pathol; 2014 May; 27(5):758-64. PubMed ID: 24186136
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.